Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors

Abstract

Although the azacitidine-epacadostat-pembrolizumab regimen was well tolerated, it was not associated with substantial clinical response in patients with advanced solid tumors previously exposed to immunotherapy.